Results 41 to 50 of about 134,090 (261)

A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer

Thoracic Cancer, 2019
To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC).
Keke Nie, Zhen Zhang, Yunhong You, Xingjun Zhuang, Chunling Zhang, Youxin Ji   +5 more
semanticscholar   +1 more source

Malignant pleural effusion and cancer of unknown primary site: a review of literature.

Annals of Translational Medicine, 2019
Malignant pleural effusions (MPE) are most frequently (50-65%) noted from lung and breast cancers. They are commonly unilateral and are reflective of poorer prognosis. Cancer of unknown primary (CUP) account for 4-5% of all invasive cancers.
S. Awadallah, M. Bowling, N. Sharma, A. Mohan   +3 more
semanticscholar   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Diagnostic value of calprotectin in differentiation between benign and malignant pleural effusion

The Egyptian Journal of Bronchology, 2019
Background Pleural effusion can arise as a result of more than 50 recognized causes and the differentiation between benign and malignant origin of the fluid is still a diagnostic challenge.
Omar M. Mohammed, Kamel M. Hussein, Abdelgawad E. Ramadan, Gouda T. Mahmoud, Marwa El-Sayed El-Naggar, Nor Eldein Z. Gaber   +5 more
doaj   +1 more source

The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer

Molecular Medicine Reports, 2018
Malignant pleural effusion (MPE) is a severe medical condition, which can result in breathlessness, pain, cachexia and reduced physical activity. It can occur in almost all types of malignant tumors; however, lung cancer is the most common cause of MPE ...
Yao Chen, N. W. Mathy, Hongda Lu
semanticscholar   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

A novel interleukin 36 gamma for diagnosing and differentiating malignant from infectious pleural effusion

Egyptian Journal of Chest Disease and Tuberculosis
Background Pleural effusions can be caused by various diseases, making their diagnosis challenging. Light’s criteria are often used to distinguish transudative and exudative effusions.
Nashwa A. Amin, Asmaa E. Mohamed, , Shimaa M.E. Wahdan, Amira E. Ramadan, Shimaa M. Mohammed, Marwa S.E. Abd-Elraouf, Kout A.M. Diab   +6 more
doaj   +1 more source

Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

Thoracic Cancer, 2019
The aim of this study was to evaluate the usefulness of the presence of malignant pleural effusion (MPE) as a negative predictor of anti‐PD‐1 antibody efficacy.
R. Shibaki, S. Murakami, Y. Shinno, Y. Matsumoto, Y. Goto, S. Kanda, H. Horinouchi, Y. Fujiwara, N. Motoi, N. Yamamoto, Y. Ohe   +10 more
semanticscholar   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Diagnostic significance of pleural fluid pH and pCO2

Egyptian Journal of Chest Disease and Tuberculosis, 2015
The diagnosis of pleural effusion is still difficult. The presence of pleural effusion can be confirmed by radiological studies including simple chest radiography, ultrasonography, or computed tomography.
K.E. Sobhey, B.A. Naglaa
doaj   +1 more source